This commentary was originally sent to Trifecta Stocks subscribers at 04:30 on April 10. The biotech group has been a mixed bag of lateChief among concerns is the issue of how new policy is going to affect pricingYet, some names have defied the rhetoric and hyperbole and just continue to move upwardsSage Therapeutics (SAGE) is one of those namesT...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.